New Alzheimer’s Treatments Are Driving a Shift in Earlier Detection and Clinician Education Engagement
June 25, 2025 |
June is Brain and Alzheimer’s Awareness Month — a chance to examine real-world data that links new treatments to changing clinical behavior.
Authors: Katie Lucero, Chief Impact Officer, Medscape; Jonathan Chee, Principal Account Manager; Anna Druet, Senior Science Writer; Briana Kelly, Senior Healthcare Consultant; Alicia Sloughfy, Senior Healthcare Consultant; Evan Woodward, MD, Senior Clinical Product Manager
Part one of a two-part series. Up next: a whitepaper delving into disparities in treatment and screening.
For years, efforts to screen for Alzheimer’s disease have lagged behind clinical need. Though over 6.9 million Americans age 65 and older are living with Alzheimer’s, the disease often goes undiagnosed. Historically, a lack of treatment options have led to limited screening by providers, even though early diagnosis can offer substantial value for many patients. In 2017, the CDC reported that only 47% of primary care physicians included cognitive assessment as part of their standard protocol for adults age 65 and older. For many families, a diagnosis still tends to come late in the disease progression. Yet early detection can provide access to support services, time to plan, and more informed care decisions.
This analysis marks the first part of a two-part series; a white paper delving into disparities in treatment and screening will be published in early fall.
New Therapies, New Incentives to Screen
The inertia may be shifting with the introduction of new treatment options. The 2023 FDA approval of lecanemab (Leqembi) — an anti-amyloid therapy (AAT) and the first approved treatment shown to reduce the rate of disease progression for early Alzheimer’s — marked a turning point. This was followed by Donanemab (Kisunla), which received FDA Breakthrough Therapy designation in 2024. Together, these therapies represent a new clinical pathway for slowing disease progression.
To understand how care is evolving in response to these approvals, we analyzed national screening trends surrounding the 2023 launch of lecanemabi. Using our MapLab® platform and our Healthcare Map® which tracks the journeys of more than 330 million U.S. patients, we assessed screening rates in the 18 months before and after July 2023. Additionally, we leveraged Medscape Education’s proprietary platform, PULSE — which reaches 95% of validated NPIs — to examine provider engagement between January 2022 and July 2024.
Among patients age 65 and older in the 18 months before and after the second DMT approval:
- Cognitive screening rose by 10%. These structured assessments support early diagnosis and help distinguish Alzheimer’s from other causes of cognitive decline
- Gene and protein biomarker testing increased by 23%. In the same cohort and timeline, more individual patients received tests like APOE genotype and plasma p-tau. While not required for treatment eligibility, these tests help clinicians assess risk and monitor disease progression, reflecting a broader move toward precision medicine
- Amyloid beta pathology testing surged more than 13-fold. In the same cohort and timeline, a far greater number of patients underwent confirmatory testing via PET imaging or cerebrospinal fluid analysis — now a prerequisite for accessing new therapies — signaling a rising demand for DMT
Impact of Clinician Education on Screening
To evaluate how new treatment approvals influence clinician knowledge and education-seeking behavior, we matched 80% of Medscape-registered clinicians who screen, diagnose, and treat Alzheimer’s with Komodo’s Healthcare Map®. These clinicians were responsible for the care of 91% of patients in the Komodo cohort.
We examined clinician content consumption, knowledge scores, and confidence ratings in the 18 months before and after the second DMT approval. Among the nearly 800,000 healthcare professionals identified as involved in the Alzheimer’s patient journey:
- Consumption of Alzheimer’s-specific independent medical education (IME) increased by 18% among clinicians involved in the Alzheimer’s journey post-approval. In contrast, those not involved in Alzheimer’s care showed a 6% increase
- Screening knowledge showed a 92% relative improvement post-approval. Clinicians scored 26% on screening-related questions pre-approval, which rose to 50% in the 18 months post-approval. Following participation in IME, knowledge scores improved by an additional 26% relative to the post-approval baseline (from 50% to 63%). Knowledge scores reflect the percentage of correct responses on three multiple-choice questions about the topic of education
- Clinician confidence in screening rose from 2.58 to 3.07 (on a five-point scale) after IME participation in the 18 months post-approval — a 19% increase. Confidence was self-rated on a scale from 1 (not at all confident) to 5 (very confident) in screening for cognitive impairment
Turning Insights Into Action
Brain and Alzheimer’s Awareness Month highlights the urgent need for improved care, and real-world evidence will play a central role in tracking how new therapies reshape clinical practice. Komodo’s tools allow stakeholders to measure the real-time impact of drug launches, surface care gaps, and drive earlier intervention across all patient populations.
Ongoing clinician education will play a critical role as the standard of care continues to evolve. Recent research has found that independent learning platforms like Medscape Education, which offers timely updates on emerging therapies and changing diagnostic protocols, help providers stay current in a fast-moving landscape. Access to accurate, up-to-date information remains essential for informed decision-making in clinical practice, especially when it comes to recognizing, screening for, and treating early signs of Alzheimer’s disease.
To explore more on screening through the lens of real-world evidence, see how disparities in diagnostic testing affect outcomes across diseases in our analysis of genetic testing gaps in ovarian cancer.
To see more articles like this, follow Komodo Health on X, LinkedIn, or YouTube, and visit Perspectives on their website.
About Medscape Education
Medscape Education is the leading online platform for continuing medical education (CME) and continuing education (CE), trusted by millions of healthcare professionals worldwide. With more than 30 speciality-specific learning destinations, it offers thousands of free, accredited courses for physicians, nurses, pharmacists, and other healthcare professionals. Medscape Education delivers high-impact, evidence-based education designed to support clinical decision-making, improve patient outcomes, and keep healthcare professionals current in a rapidly evolving medical landscape.
This content was provided by Medscape Education
Company Details
Latest Content from Medscape Education
The Heart and Mouth Connection Every Woman Needs to Know
For decades, modern medicine has treated the mouth and the body as separate entities. But for Dr. Nieca Goldberg, a renowned cardiologist, and Dr. Maria Ryan, Chief Clinical Officer at...
Uncovering Inequities in Alzheimer’s Disease Screening and Care
On December 5, MAPS hosted an educational webinar exploring recent research in Alzheimer’s disease (AD) screening, testing, and treatment. Experts from Komodo Health and Medscape shared findings from their...
Where Are We Today With Artificial Intelligence (AI) in Rare Disease Diagnosis and Care?
Discover how AI-powered tools are transforming rare disease diagnosis, patient care, and clinical decision-making.
Does Rare Disease Education Work?
For a child with a rare disease, a doctor’s continuing education can end a years-long diagnostic odyssey and unlock access to vital care.
From Genetic Puzzles to Precision Therapeutics
How was a new rare disease discovered through Singapore’s Undiagnosed Disease Program? And how will technology allow us to change how we discover rare diseases in the future? Read more...
Medscape and the GNNRD: Empowering Nurses With a Rare Disease Education Series
Nurses play a vital and multifaceted role in rare disease care, providing consistent patient support, education, and care coordination, and ongoing education is essential to empower them to meet the...
What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?
Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We...
“CGM Sweet Talk With the Sugar Queens” Takes Silver at the 2025 Digital Health Awards
Medscape Education’s dynamic educational series, CGM Sweet Talk With the Sugar Queens, has earned a Silver Award in the Video Series (Digital Health Media / Publications) category at the 2025...
Medscape at ASH 2025: Landmark Value Through the Medscape AI Debut and Five Educational Symposia
For decades, Medscape has been the brand physicians trust. Now, Medscape is forging a new path into the future at ASH 2025 with the launch of Medscape AI — the...
Women Leaders Rewriting the Protocols of Rare Disease Care
The true measure of a medical leader is the courage to act when existing systems fail the patient. This is the professional and personal ethos of clinical immunologist Dr. Hilary...